Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




Sep
16
Today In Oncology
What Constitutes Clinical Expertise in an AI-Enabled Era
American Cancer Society Urges Men to Understand Their Risk for Prostate Cancer
Two Phase III Trials Explore B7-H3–Directed ADCs in Relapsed SCLC
ADC/Immunotherapy Combination Shows Activity in Treatment-Resistant Nasopharyngeal Carcinoma
Long-Term Benefit Seen With Adjuvant Osimertinib in EGFR-Mutated NSCLC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo